SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
Granted FDA Fast Track Designation for APC Clinical CandidatePublished Comprehensive Preclinical Research on SQZ® TAC Platform in Frontiers in ImmunologyPresented First SQZ® Point-of-Care (POC) Manufacturing System Performance Data; Initial Clinical Use Planned for SQZ® TAC Celiac Disease Program with IND Submission...
United States Marshelle Smith Warren Mike Kaiser Micah Zajic Exchange Commission American Association For Cancer Research
Source: pharmiweb.com